Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era

Leukemia Research

Volumn 39, Issue 2, 2015, Pages 211-215

  Song, Moo Kon ^a   Chung, Joo Seop ^a   Lee, Gyeong won ^b   Cho, Su Hee ^c   Hong, Junshik ^d   Shin, Dong Yeop ^e   Shin, Ho Jin ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Gyeongsang National University School of Medicine   (South Korea)

^c Pusan National University Yangsan Hospital   (South Korea)

^d Gachon University   (South Korea)

^e Korea Cancer Center Hospital   (South Korea)

Author keywords

Diffuse large B cell lymphoma; Germinal center; Rituximab; Statin

Indexed keywords

ATORVASTATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PREDNISOLONE; RITUXIMAB; ROSUVASTATIN; SIMVASTATIN; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PREDNISONE; R-CHOP PROTOCOL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; VINCRISTINE;

EID: 84921434023     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.12.003     Document Type: Article

References (21)

1. Cheson B.D., Leonard J.P. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008, 359:613-626.
2. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806.
3. Berglund M., Thunberg U., Amini R.M., Book M., Roos G., Erlanson M., et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 2005, 18:1113-1120.
4. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103:275-282.
5. van Imhoff G.W., Boerma E.J., van der Holt B., Schuuring E., Verdonck L.F., Kluin-Nelemans H.C., et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:4135-4142.
6. Nyman H., Adde M., Karjalainen-Lindsberg M.L., Taskinen M., Berglund M., Amini R.M., et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007, 109:4930-4935.
7. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Naturwissenschaften 1990, 343:425-430.
8. Winiarska M., Bil J., Wilczek E., Wilczynski G.M., Lekka M., Engelberts P.J., et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008, 5:e64.
9. Arts E.E., Jansen T.L., Den Broeder A., Vonkeman H.E., Dutmer E., Van de Laar M.A., et al. Statins inhibit the anti-rheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2011, 70:877-878.
10. Cheson B.D., Pfistner B., Juweid M.E., Gascoyne R.D., Specht L., Horning S.J., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
11. Rabinowitz I. Interaction between statins and rituximab in non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:5486-5488.
12. Marignani M., Angeletti S., delle Fave G. Monoclonal antibody therapy and non-Hodgkin's lymphoma. N Engl J Med 2009, 360:192-193.
13. Cragg M.S. The potential effect of statins on rituximab immunotherapy. PLoS Med 2008, 5:e77.
14. Ennishi D., Asai H., Maeda Y., Shinagawa K., Ikeda K., Yokoyama M., et al. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2010, 21:1217-1221.
15. Nowakowski G.S., Maurer M.J., Habermann T.M., Ansell S.M., Macon W.R., Ristow K.M., et al. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 2010, 28:412-417.
16. Samaras P., Heider H., Haile S.R., Petrausch U., Schaefer N.G., Siciliano R.D., et al. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Ann Hematol 2010, 89:783-787.
17. Chan K.K., Oza A.M., Siu L.L. The statins as anticancer agents. Clin Cancer Res 2003, 9:10-19.
18. Kuoppala J., Lamminpää A., Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008, 44:2122-2132.
19. van de Donk N.W., Schotte D., Kamphuis M.M., van Marion A.M., van Kessel B., Bloem A.C., et al. Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells. Clin Cancer Res 2003, 9:5735-5748.
20. Fu K., Weisenburger D.D., Choi W.W., Perry K.D., Smith L.M., Shi X., et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008, 26:4587-4594.
21. Saito B., Shiozawa E., Usui T., Nakashima H., Maeda T., Hattori N., et al. Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma. Leukemia 2007, 21:2563-2566.